[1] WHO. HIV/AIDS[EB/OL]. (2013-10-30)[2014-4-15]. http://www.who.int/mediacentre/factsheets/fs360/en/.[2] WHO. HIV/AIDS[EB/OL]. (2013-10-30)[2014-4-15]. http://www.who.int/features/qa/71/en/.[3] POMMIER Y, JOHNSON A A, MARCHAND C. Integrase inhibitors to treat HIV/AIDS[J]. Nat Rev Drug Discov, 2005, 4(3): 236-248.[4] WILKINSON T A, JANUSZYK K, PHILLIPS M L, et al. Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase[J]. J Biol Chem, 2009, 284(12): 7931-7939.[5] DOBARD C W, BRIONES M S, CHOW S A. Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription[J]. J Virol, 2007, 81(18): 10037-10046.[6] LU R, GHORY H Z, ENGELMAN A. Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase[J]. J Virol, 2005, 79(16): 10356-10368.[7] HAZUDA D J, YOUNG S D, GUARE J P, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques[J]. Science, 2004, 305(5683): 528-532.[8] HARE S, GUPTA S S, VALKOV E, et al. Retroviral intasome assembly and inhibition of DNA strand transfer[J]. Nature, 2010, 464(7286): 232-236.[9] COCOHOBA J, DONG B J. Raltegravir: The first HIV integrase inhibitor[J]. Clin Ther, 2008, 30(10): 1747-1765.[10] FDA expands use of HIV drug Isentress to children and adolescents [EB/OL]. (2011-12-21)[2014-4-28]. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm284473.htm.[11] IWAMOTO M, WENNING L A, PETRY A S, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects[J]. Clin Pharmacol Ther, 2008, 83(2): 293-299.[12] RIZK M L, HANG Y, LUO W L, et al. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-na ve HIV-infected patients[J]. Antimicrob Agents Chemother, 2012, 56(6): 3101-3106.[13] BRAINARD D M, FRIEDMAN E J, JIN B, et al. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics[J]. J Clin Pharmacol, 2011, 51(3): 422-427.[14] HICKS C, GULICK R M. Raltegravir: The first HIV type 1 integrase inhibitor[J]. Clin Infect Dis, 2009, 48(7): 931-939.[15] LIEDTKE M D, TOMLIN C R, LOCKHART S M, et al. Long-term efficacy and safety of raltegravir in the management of HIV infection[J]. Infect Drug Resist, 2014, 7: 73-84.[16] Approval of new fixed dose combination, Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) [EB/OL]. (2012-08-27)[2014-4-29]. http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/hivandaidsactivities/ucm317204.htm.[17] European Commission Approves Gilead′s Vitekta , an Integrase Inhibitor for the Treatment of HIV-1 Infection[EB/OL]. (2013-11-18) [2014-4-29]. http://www.gilead.com/news/press-releases/2013/11/european-commission-approves-gileads-vitekta-an-integrase-inhibitor-for-the-treatment-of-hiv1-infection.[18] Gilead Sciences′ New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA[EB/OL]. (2014-04-21) [2014-4-29]. http://www.gilead.com/news/press-releases/2014/4/gilead-sciences-new-drug-applications-for-cobicistat-and-elvitegravir-for-hiv-therapy-accepted-by-us-fda.[19] RAMANATHAN S, MATHIAS A A, GERMAN P, et al. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir[J]. Clin Pharmacokinet, 2011, 50(4): 229-244.[20] MATHIAS A A, WEST S, HUI J, et al. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure[J]. Clin Pharmacol Ther, 2009, 85(1): 64-70.[21] METIFIOT M, VANDEGRAAFF N, MADDALI K, et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143[J]. AIDS, 2011, 25(9):1175-1178.[22] ELION R, MOLINA J M, RAMON ARRIBAS LOPEZ J, et al. A randomized phase 3 study comparing once-daily elvitegravir with twicedaily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results[J]. J Acquir Immune Defic Syndr, 2013, 63(4): 494-497.[23] DEEKS. Elvitegravir: A review of its use in adults with HIV-1 infection[J]. Drugs, 2014, 74(6): 687-697.[24] FDA approves new drug to treat HIV infection[EB/OL]. (2013-08-12) [2014-4-29]. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm364744.htm.[25] BALLANTYNE A D, PERRY C M. Dolutegravir: First global approval[J]. Drugs, 2013, 73(14): 1627-1637.[26] REESE M J, SAVINA P M, GENERAUX G T, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor[J]. Drug Metab Dispos, 2013, 41(2): 353-361.[27] CASTELLINO S, MOSS L, WAGNER D, et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans[J]. Antimicrob Agents Chemother, 2013, 57(8): 3536-3546.[28] SONG I, BORLAND J, CHEN S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir[J]. Antimicrob Agents Chemother, 2012, 56(3): 1627-1629.[29] WELLER S, BORLAND J, CHEN S, et al. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment[J]. Eur J Clin Pharmacol, 2014, 70(1): 29-35.[30] WAINBERG M A, MESPLEDE T, QUASHIE P K. The development of novel HIV integrase inhibitors and the problem of drug resistance[J]. Curr Opin Virol, 2012, 2(5): 656-662.[31] RAFFI F, RACHLIS A, STELLBRINK H J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study[J]. Lancet, 2013, 381(9868): 735-743.[32] CLOTET B, FEINBERG J, VAN LUNZEN J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study[J]. Lancet, 2014, 383(9936): 2222-2231.[33] New HIV drug to become leading treatment by 2016[EB/OL]. (2014-01-29) [2014-05-02] http://www. datamonitorhealthcare. com/new-hiv-drug-to-become-leading-treatment-by-2016/.[34] KAWASUJI T, JOHNS B A, YOSHIDA H, et al. Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles[J]. J Med Chem, 2013, 56(3): 1124-1135.[35] SPREEN W, MIN S, FORD S L, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK125744, an HIV integrase strand transfer inhibitor[J]. HIV Clin Trials, 2013, 14(5): 192-203.[36] MIN S, DEJESUS E, MCCURDY L, et al. Pharmacokinetics (PK) and safety in healthy and HIV-infected subjects and short-term antiviral efficacy of S/GSK1265744, a next generation once daily HIV integrase inhibitor[C]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, 2009.[37] KARMON S L, MARKOWITZ M. Next-generation integrase inhibitors: Where to after raltegravir[J]. Drugs, 2013, 73(3): 213-228.[38] CHRIST F, DEBYSER Z. The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy[J]. Virology, 2013, 435(1): 102-109.[39] DESIMMIE B A, SCHRIJVERS R, DEMEULEMEESTER J, et al. LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions[J]. Retrovirology, 2013, 10: 57.[40] FENWICK C, AMAD M, BAILEY M D, et al. Preclinical profile of BI 224436, a novel HIV-1 non-catalytic site integrase inhibitor[J]. Antimicrob Agents Chemother, 2014, 58(6): 3233-3244.[41] DI SANTO R. Diketo acids derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain[J]. Curr Med Chem, 2011, 18(22): 3335-3342.[42] ESPOSITO F, TRAMONTANO E. Past and future. Current drugs targeting HIV-1 integrase and reverse transcriptase-associated ribonuclease H activity: Single and dual active site inhibitors[J]. Antivir Chem Chemother, 2014, 23(4): 129-144.[43] COSTI R, METIFIOT M, CHUNG S, et al. Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase[J]. J Med Chem, 2014, 57(8): 3223-3234.